Screening miRNAs to Hinder the Tumorigenesis of Renal Clear Cell Carcinoma Associated with KDR Expression
- PMID: 39289946
- DOI: 10.2174/0115680096321287240826065718
Screening miRNAs to Hinder the Tumorigenesis of Renal Clear Cell Carcinoma Associated with KDR Expression
Abstract
Introduction: This study delved to understand the role of Kinase Insert Domain Receptor (KDR) and its associated miRNAs in renal cell carcinoma through an extensive computational analysis. The potential of our findings to guide future research in this area is significant.
Methods: Our methods, which included the use of UALCAN and GEPIA2 databases, as well as miRDB, MirDIP, miRNet v2.0, miRTargetLink, MiEAA v2.1, TarBase v8.0, INTERNET, and miRTarBase, were instrumental in identifying the regulation of miRNA associated with KDR expression. The predicted miRNA was validated with the TCGA-KIRC patients' samples by implementing CancerMIRNome. The TargetScanHuman v8.0 was implemented to identify the associations between human miRNAs and KDR. A Patch Dock server analyzed the interactions between hsa-miR-200c-3p and KDR.
Results: The KDR expression rate was investigated in the Kidney Renal Cell Carcinoma (KIRC) samples, and adjacent normal tissues revealed that the expression rate was significantly higher than the normal samples, which was evident from the strong statistical significance (P = 1.63e-12). Likely, the KDR expression rate was estimated as high at tumor grade 1 and gradually decreased till the metastasis grade, reducing the survival rate of the KIRC patients. To identify these signals early, we predicted a miRNA that could alter the expression of KDR. Furthermore, we uncovered the potential associations between miR-200c-3p expressions by regulating KDR towards the progression of KIRC.
Discussion: Upon examining the outcome, it became evident that miR-200c-3p was significantly downregulated in KIRC compared to the normal samples. Moreover, the negative correlation was obtained for hsa-miR-200c-3p (R = - 0.276) along with the KDR expression describing that the increased rate of hsamiR- 200c-3p might reduce the KDR expression rate, which may suppress the KIRC initiation or progression.
Conclusion: The in-silico analysis indicated that the significant increase in KDR expression during the initiation of KIRC could serve as an early diagnostic marker. Moreover, KDR could be utilized to identify advancements in KIRC stages. Additionally, hsa-miR-200c-3p was identified as a potential regulator capable of downregulating and upregulating KDR expression among the 24 miRNAs screened. This finding holds promise for future research endeavors. Concurrent administration of the FDA-approved 5- fluorouracil with KIRC drugs, such as sorafenib, zidovudine, and everolimus, may have the potential to enhance the therapeutic efficacy in downregulating hsa-miR-200c-3p. However, further in vitro studies are imperative to validate these findings and gain a comprehensive understanding of the intricate regulatory interplay involving hsa-miR-200c-3p, KDR, 5-fluorouracil, and other FDA-approved drugs for the treatment of KIRC. This will facilitate the identification of KIRC stage progression and its underlying preventative mechanisms.
Keywords: KDR; computational kidney; miR-200c-3p.; miRNA; renal cell carcinoma; tumor grade potential regulator.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Similar articles
-
Exosome-derived hsa-miR-200c-3p, hsa-miR-25-3p and hsa-miR-301a-3p as potential biomarkers and therapeutic targets for restoration of PTEN expression in clear cell renal cell carcinoma.Int J Biol Macromol. 2025 Apr;302:140607. doi: 10.1016/j.ijbiomac.2025.140607. Epub 2025 Feb 1. Int J Biol Macromol. 2025. PMID: 39900161
-
Comprehensive analysis of PTEN-related ceRNA network revealing the key pathways WDFY3-AS2 - miR-21-5p/miR-221-3p/miR-222-3p - TIMP3 as potential biomarker in tumorigenesis and prognosis of kidney renal clear cell carcinoma.Mol Carcinog. 2022 May;61(5):508-523. doi: 10.1002/mc.23396. Epub 2022 Feb 7. Mol Carcinog. 2022. PMID: 35129856
-
A microRNA-clinical prognosis model to predict the overall survival for kidney renal clear cell carcinoma.Cancer Med. 2021 Sep;10(17):6128-6139. doi: 10.1002/cam4.4148. Epub 2021 Jul 21. Cancer Med. 2021. PMID: 34288551 Free PMC article.
-
MicroRNA related prognosis biomarkers from high throughput sequencing data of kidney renal clear cell carcinoma.BMC Med Genomics. 2021 Mar 9;14(1):72. doi: 10.1186/s12920-021-00932-z. BMC Med Genomics. 2021. PMID: 33750388 Free PMC article.
-
MicroRNA networks in prolactinoma tumorigenesis: a scoping review.Cancer Cell Int. 2024 Dec 19;24(1):418. doi: 10.1186/s12935-024-03529-5. Cancer Cell Int. 2024. PMID: 39702128 Free PMC article.
Cited by
-
Targeting miRNAs in renal cell carcinoma: emerging therapeutic strategies.Int J Clin Oncol. 2025 Aug 21. doi: 10.1007/s10147-025-02856-5. Online ahead of print. Int J Clin Oncol. 2025. PMID: 40839233 Review.
References
-
- Brown J.E.; Royle K.L.; Gregory W.; Ralph C.; Maraveyas A.; Din O.; Eisen T.; Nathan P.; Powles T.; Griffiths R.; Jones R.; Vasudev N.; Wheater M.; Hamid A.; Waddell T.; McMenemin R.; Patel P.; Larkin J.; Faust G.; Martin A.; Swain J.; Bestall J.; McCabe C.; Meads D.; Goh V.; Min Wah T.; Brown J.; Hewison J.; Selby P.; Collinson F.; Carser J.; Srinivasan G.; Thistlewaite F.; Azzabi A.; Beresford M.; Farrugia D.; Decatris M.; Thomas C.; Gale J.; McAleer J.; Clayton A.; Boleti E.; Geldart T.; Sundar S.; Lester J.; Palaniappan N.; Hingorani M.; Rehman K.; Khan M.; Sarwar N.; Graham J.; Thomson A.; Srihari N.; Sheehan D.; Srinivasan R.; Khan O.; Jane Worlding A.S.; Boussios S.; Stuart N.; MacDonald-Smith C.; Danwata F.; McLaren D.; Sundaramurthy A.; Lydon A.; Beesley S.; Lees K.; Varughese M.; Gray E.; Scott A.; Baxter M.; Mullard A.; Innominato P.; Kapur G.; Kumar A.; Charnley N.; Manetta C.; Chakraborti P.; Das P.; Rudman S.; Taylor H.; Mikropoulos C.; Highley M.; Muthukumar D.; Zarkar A.; Vergis R.; Sriprasad S.; Brulinski P.; Clarke A.; Osbourne R.; Harvey M.; Dega R.; Sparrow G.; Barthakur U.; Beaumont E.; Manetta C.; Michael A.; Porfiri E.; Azam F.; Kodavtiganti R.; Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): An open-label, non-inferiority, randomised, controlled, phase 2/3 trial. Lancet Oncol 2023,24(3),213-227 - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical